Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 24, 2013

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Juvenile Myelomonocytic Leukemia
Interventions
PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allogeneic HCT

DRUG

Busulfan

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Melphalan

Given IV

DRUG

Mycophenolate Mofetil

Given IV or PO

OTHER

Pharmacological Study

Correlative studies

DRUG

Tacrolimus

Given IV or PO

Trial Locations (50)

1145

Starship Children's Hospital, Grafton

6008

Princess Margaret Hospital for Children, Perth

10032

Columbia University/Herbert Irving Cancer Center, New York

10467

Montefiore Medical Center - Moses Campus, The Bronx

10595

New York Medical College, Valhalla

14642

University of Rochester, Rochester

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

19803

Alfred I duPont Hospital for Children, Wilmington

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

29425

Medical University of South Carolina, Charleston

30322

Children's Healthcare of Atlanta - Egleston, Atlanta

32207

Nemours Children's Clinic-Jacksonville, Jacksonville

33701

Johns Hopkins All Children's Hospital, St. Petersburg

35233

Children's Hospital of Alabama, Birmingham

39216

University of Mississippi Medical Center, Jackson

40202

Norton Children's Hospital, Louisville

43205

Nationwide Children's Hospital, Columbus

44106

Rainbow Babies and Childrens Hospital, Cleveland

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Riley Hospital for Children, Indianapolis

48201

Wayne State University/Karmanos Cancer Institute, Detroit

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

53792

University of Wisconsin Hospital and Clinics, Madison

55455

University of Minnesota/Masonic Cancer Center, Minneapolis

60611

Lurie Children's Hospital-Chicago, Chicago

63104

Cardinal Glennon Children's Medical Center, St Louis

64108

The Childrens Mercy Hospital, Kansas City

68198

University of Nebraska Medical Center, Omaha

73104

University of Oklahoma Health Sciences Center, Oklahoma City

75230

Medical City Dallas Hospital, Dallas

75390

UT Southwestern/Simmons Cancer Center-Dallas, Dallas

76104

Cook Children's Medical Center, Fort Worth

78229

Methodist Children's Hospital of South Texas, San Antonio

84113

Primary Children's Hospital, Salt Lake City

85016

Phoenix Childrens Hospital, Phoenix

90095

Mattel Children's Hospital UCLA, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

92123

Rady Children's Hospital - San Diego, San Diego

92868

Children's Hospital of Orange County, Orange

94143

UCSF Medical Center-Parnassus, San Francisco

94158

UCSF Medical Center-Mission Bay, San Francisco

97239

Oregon Health and Science University, Portland

98105

Seattle Children's Hospital, Seattle

02215

Dana-Farber Cancer Institute, Boston

07601

Hackensack University Medical Center, Hackensack

V6H 3V4

British Columbia Children's Hospital, Vancouver

R3E 0V9

CancerCare Manitoba, Winnipeg

H3H 1P3

The Montreal Children's Hospital of the MUHC, Montreal

H3T 1C5

Centre Hospitalier Universitaire Sainte-Justine, Montreal

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Children's Oncology Group

NETWORK

NCT01824693 - Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia | Biotech Hunter | Biotech Hunter